Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May 8;397(10286):1685-1687.
doi: 10.1016/S0140-6736(21)00870-9. Epub 2021 Apr 23.

Population immunity and vaccine protection against infection

Eyal Leshem  1 , Benjamin Alan Lopman  2
Affiliations
Comment

Population immunity and vaccine protection against infection

Eyal Leshem et al. Lancet. .
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gallagher ME, Sieben AJ, Nelson KN, et al. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates. Nat Med. 2021;27:4–5. - PMC - PubMed
    1. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495–500. - PMC - PubMed
    1. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 doi: 10.1038/s41591-021-01316-7. published online March 29. - DOI - PubMed
    1. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397:875–877. - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed